Bruno horisberger (56 resultados)

Condición: Fair. This is an ex-library book and may have the usual library/used-book markings inside.This book has hardback covers. Clean from markings. In fair condition, suitable as a study copy. No dust jacket. Please note the Image in this listing is a stock photo and may not match the covers of the actual item,700grams, ISBN:354018662X.…

Cloth. Condición: Fine. No Jacket. First Edition. This is a fine, unmarked, hardcover first edition copy, blue cloth binding, no DJ.

Hardcover. XV, 244 S. : 52 Ill. u. graph. Darst. ; 25 cm Good condition. Reading pages are clean and without marks. Retired library exemplar, with the usual marking. Corners slightly rubbed or bumped. 9783540186625 Sprache: Englisch Gewicht in Gramm: 615.

Hard Cover. Condición: Very Good. No Jacket. First Edition. Lightly worn copy.

Condición: New.

Condición: Sehr gut. Auflage: 1. 240 Seiten Sehr gutes Exemplar 55 9783540505341 Sprache: Englisch Gewicht in Gramm: 626 0,0 x 0,0 x 0,0 cm, Gebundene Ausgabe.

hardcover. Condición: Gut. 359 Seiten; 9783540535058.3 Gewicht in Gramm: 1.

hardcover. Condición: Sehr gut. 359 Seiten; 9783540535058.2 Gewicht in Gramm: 1.

Paperback. Condición: Brand New. 264 pages. 9.61x6.69x0.60 inches. In Stock.

Taschenbuch. Condición: Neu. Druck auf Anfrage Neuware - Printed after ordering - Modern drugs are invented according to medical needs, making use of the latest innovations in technology. They are sophisticated, efficacious, and costly, but are they effective Are they superior to existing - and cheaper - alternatives, and is this superiority reflected in increased cost-effectiveness Are they socially more beneficial These questions, and those related to the intriguing search for better quality of life, are addressed in this book by experts from the fields of medicine, epidemiology, economics, sociology and the pharmaceutical industry. The book describes the environmental situation in the United States and Europe in which pharmaceutical development takes place; it also explores the grounds for agreement as well as disagreement between the social and the economic evaluations of progress. It tackles the problem of outcome measurements, patients' behavior, quality of life, and individual value judgments and describes methodological boundaries in the socioeconomic evaluation of drugs.…

hardcover. Condición: Sehr gut. 240 Seiten; 9783540505341.2 Gewicht in Gramm: 1.

Condición: As New. Unread book in perfect condition.

Condición: New.

Condición: New.

Taschenbuch. Condición: Neu. Druck auf Anfrage Neuware - Printed after ordering - In the past two decades public debate about the risks, benefits, and safety associated with drugs has intensified. Public disputes over risks are brought to court when individuals seek compensation for health problems attributed to a pharmaceutical product. The issue reaches legislatures and regulatory agencies when consumer advocates seek to influence the standards of drug usage. Front-page news tends to focus on accidents or other risk events with drugs. Drug risk and drug safety have become an important political issue. Drug regulat ory agencies have been instituted, and their responsibility has increased. The approval to market a drug is dependent on a set of sophisticated studies executed according to strict protocols and scientifically defined criteria. Drug surveillance activities have gained recognition, and reporting systems to identify drug safety problems have been strengthened. The understanding and management of drug safety is, nonetheless, beset by doubts, disagreements, and disputes. Conflict occurs over the significance of risk, the adequacy of evidence, the methodologies used to evaluate and measure risk, the standards that guide regulation, and the optimal means of communicating risk information to the public.…

Condición: New. pp. xxiii + 210.

Paperback. Condición: Brand New. reprint edition. 240 pages. 9.40x6.80x0.60 inches. In Stock.

Paperback. Condición: Like New. LIKE NEW. SHIPS FROM MULTIPLE LOCATIONS. book.

Condición: As New. Unread book in perfect condition.

Condición: New.

Condición: As New. Unread book in perfect condition.

Condición: Sehr gut. Zustand: Sehr gut | Sprache: Englisch | Produktart: Bücher | In the past two decades public debate about the risks, benefits, and safety associated with drugs has intensified. Public disputes over risks are brought to court when individuals seek compensation for health problems attributed to a pharmaceutical product. The issue reaches legislatures and regulatory agencies when consumer advocates seek to influence the standards of drug usage. Front-page news tends to focus on accidents or other risk events with drugs. Drug risk and drug safety have become an important political issue. Drug regulat­ ory agencies have been instituted, and their responsibility has increased. The approval to market a drug is dependent on a set of sophisticated studies executed according to strict protocols and scientifically defined criteria. Drug surveillance activities have gained recognition, and reporting systems to identify drug safety problems have been strengthened. The understanding and management of drug safety is, nonetheless, beset by doubts, disagreements, and disputes. Conflict occurs over the significance of risk, the adequacy of evidence, the methodologies used to evaluate and measure risk, the standards that guide regulation, and the optimal means of communicating risk information to the public.…

Taschenbuch. Condición: Neu. Druck auf Anfrage Neuware - Printed after ordering - As the focus on pharmaceuticals has broadened from concern for their cost and effectiveness to their real and potential risks and benefits, a critical question has been raised: whose responsibility is it to improve drug safety In April 1990, this question became the theme for a conference at Wolfsberg, Switzerland, near the shores of Lake Constance. Called an 'international dialogue conference' by its organizers, the meeting brought together leaders from the pharmaceutical industry, regulatory authorities, academia, medicine, consumer organizations and the media. Opening addresses were given by representatives of the Council for International Organizations of Medical Sciences (CIOMS), the International Federation of Pharmaceutical Manufacturers Associations (IFPMA), the Swiss International Pharmaceutical Agency, and the RAD-AR Consortium. This book documents the papers presented and discussions held at this conference, which took the topic of risks and benefits of drug therapy one step further to responsibility. It includes a rich menu of issues for those who care about the evaluation of drug therapy, the ethics behind it, the expectations of the patient, and the role of traditional and nontraditional drug safety communica tions. The ideas expressed here come from different parts of the world but relate to common drug safety problems, observations, and scientific assessments; they provide insights into innovative approaches, cautious changes, and desired actions. The papers in this volume are broadly divided into conceptual perspectives (ethics, how the knowledge about drug risks and benefits is generated and appraised, the expectations in drug safety) and operational perspectives (communication, discussion, and action).…

Condición: gut. 1989. The Perception and Management of Drug Safety Risks: International Conference : Papers (Health Systems Research) In deutscher Sprache. pages.

Condición: New. pp. xxi + 338.

Paperback. Condición: Brand New. reprint edition. 359 pages. 9.53x0.82x6.69 inches. In Stock.

Condición: As New. Unread book in perfect condition.

Condición: New.

Condición: As New. Unread book in perfect condition.

Taschenbuch. Condición: Neu. Druck auf Anfrage Neuware - Printed after ordering - Unter dem Eindruck der Kostenentwicklung im Gesundheitswesen gewinnen oko nomische Uberlegungen im Gesundheitswesen zunehmend an Bedeutung. Die Notwendigkeit, den Gesundheitszustand effektiv und efftzient zu verbessem, ruft nach einer Auswahl wirkungsvoller Verfahren aufgrund objektivierbarer Kriterien. In der heudgen Situation kann die friiher geauBerte Ansicht, daB Geld keine Rolle spielen durfe, wo Gesundheit und das menschliche Wohlbefinden auf dem Spiel stehen, nicht mehr langer aufrechterhalten werden, da sie bei beschrankten Mitteln unweigerlich zu Ungleichheiten in der Behandlung fuhren muBte. Die vielfaltigen Anforderungen an den modemen Sozialstaat verpflichten vielmehr alle Beteiligten zu einem moglichst rationellen Einsatz der Ressourcen, unter Abwagen der Beurtei lung der Altemativen. Der Ruf nach Methoden zur Bewertung der Leistungen des Gesundheitswesens und des Nutzens der einzelnen Verfahren ist nicht neu. Es sind jetzt gut 20 Jahre her, seit Fuchs seine Monographie unter dem Titel ,Who shalllive 'l veroffentlicht hat und darin das zentrale Thema der Auswahl verschiedener Verfahren auf indivi dueller und auf sozialer Ebene als Notwendigkeit fUr das Gesundheitswesen ent wickelte. …